rifampicin/isoniazid/ethambutol/pyrazinamide / Generic mfg. - LARVOL DELTA

When Evidence Eludes: The Diagnostic Complexity of Abdominal Tuberculosis Mimicking Sarcoidosis (ACG 2026) - "Given the high clinical suspicion, empiric antituberculous therapy (rifampin, isoniazid, pyrazinamide, ethambutol) was initiated despite the lack of microbiologic confirmation...Figure: Moderate abdominopelvic Ascites ( black Arrow ) with enhancement of parietal peritoneum and mild peritoneal nodularity. Figure: Multiple Prominent pelvic and retroperitoneal Lymph nodes"

Anorexia • Constipation • Gastroenterology • Gastrointestinal Disorder • Human Immunodeficiency Virus • Immunology • Infectious Disease • Respiratory Diseases • Sarcoidosis • Tuberculosis

S31PK/PD: Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (clinicaltrials.gov) - P3 | N=2516 | Completed | Sponsor: Centers for Disease Control and Prevention | N=53 ➔ 2516

Enrollment change • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

SYNERGY: Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis (clinicaltrials.gov) - P2 | N=135 | Not yet recruiting | Sponsor: TASK Applied Science

New P2 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

MCC04. Medically Challenging Cases 4: Cardiac Anesthesia - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME • Anesthesia

MCC124. Medically Challenging Cases 124: Critical Care - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME • Critical care

QI04. Quality Improvement Projects 4: Perioperative Medicine - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

MCC24. Medically Challenging Cases 24: Cardiac Anesthesia - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME • Anesthesia

MCC84. Medically Challenging Cases 84: Critical Care - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME • Critical care

MCC44. Medically Challenging Cases 44: Neuroanesthesia - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME

MCC64. Medically Challenging Cases 64: Critical Care - Monitor 4 (Non-CME) (ASA 2026) - No abstract available

Clinical • CME • Critical care

Wearable sweat sensor system with dynamically adjustable sensitivity for simultaneous detection of multiple biomarkers. (PubMed, Talanta) - "To further realize multi-channel synchronous acquisition, the system employs a numerically controlled switch circuit combined with a time-division multiplexing strategy and dual TIA channels to simultaneously monitor 4 types of sweat biomarkers. During in vivo cycling experiments, the sensor system successfully demonstrated in vivo monitoring of 4 biomarkers in human sweat. This study provides an effective technical solution for multi-biomarker detection and health monitoring with a wide detection range."

Biomarker • Journal

ISONIAZID AND PYRAZINAMIDE INDUCED PELLAGRA IN A CHILD WITH CERVICAL LYMPH NODE TUBERCULOSIS (ESPID 2026) - "Case Presentation Summary An 11-year-old girl was diagnosed with rifampicin-sensitive cervical lymph node tuberculosis in June 2025 by biopsy and Xpert/Rif positivity, was started on standard first-line antitubercular therapy with rifampicin, isoniazid, ethambutol, pyrazinamide, and pyridoxine...Subsequently, isoniazid and pyrazinamide were discontinued, and treatment was modified to rifampicin and ethambutol with the addition of levofloxacin, following which patient showed clinical improvement...Susceptibility is higher in slow acetylators. Early clinical recognition and prompt treatment with nicotinamide and nutritional support are crucial to prevent serious complications."

Clinical • Infectious Disease • Tuberculosis

Rifampicin at High Dose for Difficult-to-Treat Tuberculosis (RIAlta) study (clinicaltrialsregister.eu) - P1/2 | N=50 | Recruiting | Sponsor: Fundacio Hospital Universitari Vall DHebron Institut De Recerca | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Isolated epididymal tuberculosis presenting as a chronic hydrocele: A rare manifestation of genitourinary TB. (PubMed, IDCases) - "The patient completed nine months of standard anti-tuberculosis therapy comprising intensive phase (rifampicin, isoniazid, pyrazinamide, ethambutol for two months) followed by continuation phase (rifampicin and isoniazid for seven months) with complete clinical and radiological resolution...In tuberculosis-endemic regions, maintaining high clinical suspicion for tuberculosis even in routine scrotal pathology is essential. Epididymal tuberculosis should be considered in differential diagnosis of chronic hydrocele, particularly in endemic areas, and routine histopathological examination of all surgical specimens with multidisciplinary collaboration remains crucial for timely diagnosis and appropriate management."

Journal • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis

AIPH-TB-RCT-P2: AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Ministry of Health, Saudi Arabia

New P2 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

BIOMARK4TB: Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment (clinicaltrialsregister.eu) - P4 | N=75 | Recruiting | Sponsor: Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Biomarker • New P4 trial • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Retrieval Augmented Generation (RAG) for Evaluating Regulatory Compliance of Drug Information and Clinical Trial Protocols. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "The drug information for adalimumab, insulin glargine, atorvastatin calcium, sertraline, and alprazolam was evaluated for compliance with Food and Drug Administration (FDA) clinical pharmacology guidance for indications, use in specific populations, and warnings and precautions. The reasons for the withdrawal of rofecoxib, valdecoxib, and troglitazone were elicited. The clinical trial protocol evaluation system was used to assess a Phase-2a clinical trial protocol of Rifafour in tuberculosis with the FDA E9 and E9 (R1) guidance documents...The findings aligned with manual protocol reviews. RAG-based AI methods can improve the usefulness of LLMs in document-restricted settings and are a promising approach for evaluating the compliance of clinical pharmacology documents."

Compliance • Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Chasing shadows: case series of six posterior segment manifestations of ocular tuberculosis. (PubMed, AME Case Rep) - "All patients received standard RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) therapy with a tapered oral corticosteroid course...In endemic regions, early suspicion supported by TST/IGRA and multimodal imaging, followed by RIPE plus corticosteroids, can control inflammation and mitigate vision-threatening complications. Vigilance for secondary choroidal neovascularization (CNV) and timely surgical intervention is essential."

Journal • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Tuberculosis • Uveitis • Vasculitis

Miliary tuberculosis complicated by tuberculous vasculitis and ischemic stroke in a 16-year-old female patient: a case report. (PubMed, J Med Case Rep) - "This case highlights the challenges of managing miliary tuberculosis with complications such as vasculitis and ischemic stroke. Early diagnosis and a comprehensive treatment approach, including antituberculosis therapy and rehabilitation, led to significant improvement. It underscores the need for strengthened healthcare systems and timely interventions to improve outcomes in complex tuberculosis cases."

Journal • Cardiovascular • Cough • Infectious Disease • Ischemic stroke • Pulmonary Disease • Respiratory Diseases • Tuberculosis • Vasculitis

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Thirty Respiratory Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Cerebral Abscess Masquerading as Tuberculoma in a Post-Renal Transplant Chronic Kidney Disease Patient: A Diagnostic and Therapeutic Challenge. (PubMed, Clin Case Rep) - "Laboratory investigations revealed significant renal impairment, persistent hyponatremia, hypokalemia, and subtherapeutic tacrolimus levels (2.50 ng/mL), reflecting challenges of CKD and chronic immunosuppression with mycophenolate mofetil and tacrolimus. Treatment included intravenous ceftriaxone, dexamethasone, and a CKD-adjusted anti-TB regimen (rifampicin, isoniazid, ethambutol, pyrazinamide), alongside phenytoin and continued immunosuppressants. This case underscores the diagnostic complexity of distinguishing cerebral abscesses from tuberculomas in post-transplant patients, highlighting the pivotal role of multi-modal imaging (MRI, MRS) and tailored therapy to manage infection, immunosuppression, and comorbidities effectively."

Journal • Brain Cancer • Cardiovascular • Chronic Kidney Disease • Diabetes • Glioma • Heart Failure • High Grade Glioma • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Respiratory Diseases • Solid Organ Transplantation • Solid Tumor • Transplantation

NEW-STRAT TB: Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis (clinicaltrials.gov) - P3 | N=732 | Active, not recruiting | Sponsor: University of Cape Town | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Mar 2026 | Trial primary completion date: Jun 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

1H-NMR-based metabolomics study of Rifafour in a healthy Kramnik (C3HeB/FeJ) tuberculosis mouse model. (PubMed, Front Pharmacol) - "That is, these findings highlight the need to distinguish drug-induced metabolic abnormalities from those resulting from infections, consequently aiding the interpretation of metabolomic data in tuberculosis research and improving the development of more accurate therapeutic and diagnostic approaches. Hence, future studies can focus on the perturbed metabolites from TB and account for metabolites resulting from anti-TB medication, as shown in this study."

Journal • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Hepatic disseminated mycobacterium infection: a case report and a literature review. (PubMed, AME Case Rep) - "Following diagnosis, the patient was treated with rifampin, isoniazid, pyrazinamide, ethambutol, and clarithromycin. For patients with multi-organ disseminated infection involving the liver, conventional anti-tuberculosis drugs are less effective, and the infection continues to pose a serious threat that should be considered a high priority. When formulating NTM chemotherapy regimens, combination therapy should be selected based on drug susceptibility testing results, and ongoing monitoring of both drug sensitivity and safety should be ensured throughout the treatment process."

Journal • Gastroenterology • Hepatology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Lower Lobe, Higher Suspicion: An Atypical Presentation of Pulmonary Tuberculosis. (PubMed, Cureus) - "The patient was discharged home on standard RIPE (rifampin, isoniazid, pyrazinamide, ethambutol) therapy for six months and instructed to follow up with his primary care physician. This case highlights the atypical nature of this patient's presentation regarding the location of their TB infection, as well as the absence of traditional risk factors associated with TB. In this case, we will discuss the diagnostic challenges associated with atypical TB cases and how occupational exposures may contribute to the onset, severity, or location of TB infection."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis